Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CER-001 Dose-Finding Trial in Acute Coronary Syndrome
2010-023611-34Phase 2Completed
- Sponsor
- ABIONYX Pharma
- Start
- May 2011
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CER-001 in acute coronary syndrome (ACS), myocardial infarction (MI), unstable angina and 1 more (4 arms), sponsored by ABIONYX Pharma. Primary endpoint: Change in total plaque volume in target coronary artery segment. Started May 2011; status: completed.
02
Drugs
CER-001
03
Conditions
acute coronary syndrome (ACS)myocardial infarction (MI)unstable anginacoronary arteriosclerosis
Beyond the preview
Go deeper on 2010-023611-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023611-34.